Sojung Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sojung Lim has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Yoon Kyung Jeon
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - Jeemin Yim
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
3 shared publications - Sehui Kim
Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Young Keun Song
Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
3 shared publications - Bogyeong Han
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Cheol Lee
Department of Pathology, Seoul National University Hospital, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Evaluation of point-of-care testing (POCT) for blood-borne infections in forensic autopsy specimens
Lateral flow immunoassay (LFIA)-based point-of-care testing (POCT) for viral antigen and antibody detection enables rapid screening for blood-borne viral infections and may be particularly valuable in forensic autopsy settings, where incomplete antemortem medical histories and invasive procedures increase the risk of occupational exposure. However, its performance in postmortem specimens remains unclear. We evaluated the applicability of LFIA-based POCT for detecting human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in autopsy specimens, focusing on postmortem decomposition and the use of solid organ tissues as alternatives to blood. A total of 309 cases were analyzed using LFIA and quantitative polymerase chain reaction (qPCR) across blood, liver, and spleen specimens. Agreement was assessed using overall, positive, and negative percent agreement and Cohen’s kappa coefficient ( κ ). Positivity rates were compared by specimen type and decomposition status. LFIA agreement with qPCR varied by marker and specimen type, with substantial agreement for HIV and HCV antibody detection in blood and lower agreement in liver and spleen. Fresh specimens generally demonstrated higher LFIA positivity rates than decomposed specimens. Among specimens meeting predefined qPCR positivity criteria, LFIA-positive specimens tended to exhibit higher viral loads than LFIA-negative specimens, reaching statistical significance for HBV in liver, with similar but non-significant trends for blood HBV and liver HCV. LFIA-based POCT may serve as a preliminary screening tool in postmortem settings, particularly when blood is available. Nevertheless, negative results do not exclude infection—especially with low viral loads or advanced decomposition—and should be confirmed by molecular testing. IMPORTANCE: Forensic personnel performing autopsies face significant occupational risks from exposure to blood-borne viruses, including human immunodeficiency virus, hepatitis B virus, and hepatitis C virus. Unlike clinical settings, forensic autopsies frequently involve bodies with unknown infection histories, making rapid infection screening essential for personnel safety. Lateral flow immunoassay (LFIA)-based point-of-care testing (POCT) for viral antigen and antibody detection offers a rapid, infrastructure-free screening option; however, its performance in postmortem specimens has not been systematically evaluated. This study suggests that rapid immunochromatographic POCT may serve as a preliminary screening tool in forensic autopsy settings, particularly when blood specimens are available. However, a negative result does not exclude infection, especially in cases with low viral load or advanced decomposition, and confirmatory molecular testing remains necessary. These findings provide practical guidance for forensic professionals on appropriate specimen selection and interpretation of LFIA results, ultimately supporting safer autopsy practices.
- 11 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Open AccessEvaluation of point-of-care testing (POCT) for blood-borne infections in forensic autopsy specimens
Lateral flow immunoassay (LFIA)-based point-of-care testing (POCT) for viral antigen and antibody detection enables rapid screening for blood-borne viral infections and may be particularly valuable in forensic autopsy settings, where incomplete antemortem medical histories and invasive procedures increase the risk of occupational exposure. However, its performance in postmortem specimens remains unclear. We evaluated the applicability of LFIA-based POCT for detecting human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in autopsy specimens, focusing on postmortem decomposition and the use of solid organ tissues as alternatives to blood. A total of 309 cases were analyzed using LFIA and quantitative polymerase chain reaction (qPCR) across blood, liver, and spleen specimens. Agreement was assessed using overall, positive, and negative percent agreement and Cohen’s kappa coefficient ( κ ). Positivity rates were compared by specimen type and decomposition status. LFIA agreement with qPCR varied by marker and specimen type, with substantial agreement for HIV and HCV antibody detection in blood and lower agreement in liver and spleen. Fresh specimens generally demonstrated higher LFIA positivity rates than decomposed specimens. Among specimens meeting predefined qPCR positivity criteria, LFIA-positive specimens tended to exhibit higher viral loads than LFIA-negative specimens, reaching statistical significance for HBV in liver, with similar but non-significant trends for blood HBV and liver HCV. LFIA-based POCT may serve as a preliminary screening tool in postmortem settings, particularly when blood is available. Nevertheless, negative results do not exclude infection—especially with low viral loads or advanced decomposition—and should be confirmed by molecular testing. IMPORTANCE: Forensic personnel performing autopsies face significant occupational risks from exposure to blood-borne viruses, including human immunodeficiency virus, hepatitis B virus, and hepatitis C virus. Unlike clinical settings, forensic autopsies frequently involve bodies with unknown infection histories, making rapid infection screening essential for personnel safety. Lateral flow immunoassay (LFIA)-based point-of-care testing (POCT) for viral antigen and antibody detection offers a rapid, infrastructure-free screening option; however, its performance in postmortem specimens has not been systematically evaluated. This study suggests that rapid immunochromatographic POCT may serve as a preliminary screening tool in forensic autopsy settings, particularly when blood specimens are available. However, a negative result does not exclude infection, especially in cases with low viral load or advanced decomposition, and confirmatory molecular testing remains necessary. These findings provide practical guidance for forensic professionals on appropriate specimen selection and interpretation of LFIA results, ultimately supporting safer autopsy practices.
- Open Access
- 31 August 2026
- Published by The Korean Society for Legal Medicine in Korean Journal of Legal Medicine
- Vol. 50 (3) , 106-111
An Incidentally Detected 46,XY Disorder of Sex Development during Kinship Testing
In forensic short tandem repeat (STR) analysis, sex typing is routinely performed using markers such as amelogenin, Y-STRs, and Y-insertion/deletion polymorphisms (Y-InDels). Although autosomal STR markers are not intended to reveal health-related information, sex typing may incidentally reveal disorders of sex development (DSDs). Herein, we present the case of a 73-year-old woman in whom a 46,XY DSD was incidentally identified during kinship testing. Both AMELX and AMELY were detected with similar peak heights in STR analysis, along with the detection of Y-STR and Y-InDel markers. Furthermore, Y- and X-STR analyses showed complete Y-STR profiles and hemizygosity across all X-STR loci, suggesting an XY chromosomal constitution. The participant reported a history of primary amenorrhea, and 46,XY DSD was suspected. Targeted sequencing of 63 DSD-related genes revealed a splice donor site variant in the androgen receptor (AR) gene (c.2173+1G>A), suggesting androgen insensitivity syndrome. Although rare, discordance between chromosomal sex determined by DNA testing and phenotype may indicate an underlying DSD, and further diagnostic evaluation and medical intervention may be warranted. Referral to an appropriate medical professional may be necessary, although not the original purpose of testing. However, the disclosure of such incidental findings can raise ethical concerns, including privacy issues and should be communicated with caution. Finally, forensic professionals should be aware of the limitations of sex typing and its potential to be misleading in investigative contexts, where sex inferred from STR typing can lead to the exclusion of suspects.
- 31 August 2026
- Published by The Korean Society for Legal Medicine in Korean Journal of Legal Medicine
- Vol. 50 (3) , 106-111
Open AccessAn Incidentally Detected 46,XY Disorder of Sex Development during Kinship Testing
In forensic short tandem repeat (STR) analysis, sex typing is routinely performed using markers such as amelogenin, Y-STRs, and Y-insertion/deletion polymorphisms (Y-InDels). Although autosomal STR markers are not intended to reveal health-related information, sex typing may incidentally reveal disorders of sex development (DSDs). Herein, we present the case of a 73-year-old woman in whom a 46,XY DSD was incidentally identified during kinship testing. Both AMELX and AMELY were detected with similar peak heights in STR analysis, along with the detection of Y-STR and Y-InDel markers. Furthermore, Y- and X-STR analyses showed complete Y-STR profiles and hemizygosity across all X-STR loci, suggesting an XY chromosomal constitution. The participant reported a history of primary amenorrhea, and 46,XY DSD was suspected. Targeted sequencing of 63 DSD-related genes revealed a splice donor site variant in the androgen receptor (AR) gene (c.2173+1G>A), suggesting androgen insensitivity syndrome. Although rare, discordance between chromosomal sex determined by DNA testing and phenotype may indicate an underlying DSD, and further diagnostic evaluation and medical intervention may be warranted. Referral to an appropriate medical professional may be necessary, although not the original purpose of testing. However, the disclosure of such incidental findings can raise ethical concerns, including privacy issues and should be communicated with caution. Finally, forensic professionals should be aware of the limitations of sex typing and its potential to be misleading in investigative contexts, where sex inferred from STR typing can lead to the exclusion of suspects.
- Open Access
- 12 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 1929-1942
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel
Several molecular subclassifications of diffuse large B-cell lymphoma (DLBCL) with prognostic and therapeutic potential have been proposed; however, validation in diverse populations and real-world clinical settings remains limited. We investigated the genetic subtypes of Korean DLBCL using the LymphGen classifier and an institutionally developed 121-gene targeted next-generation sequencing (NGS) panel. We also assessed quality control metrics, copy number reliability, and benchmarking performance against an external reference data set (Memorial Sloan Kettering Cancer Center–Integrated Mutation Profiling Actionable Cancer Targets). LymphGen subtypes differed by entity. Patients with DLBCL, not otherwise specified (DLBCL-NOS; n = 123) were classified as MCD (25.2%), A53 (14.6%), ST2 (7.3%), BN2 (5.7%), EZB (3.3%), composite EZB/ST2 (1.6%), and unclassified (“other”; 42.3%). Patients with primary DLBCLs of the central nervous system (n = 77) were classified as MCD (70.1%), composite MCD/A53 (2.6%), A53 (3.9%), BN2 (2.6%), ST2 (1.3%), EZB (1.3%), and “other” (18.2%). Compared with Western cohorts, the LymphGen subtype distribution in our Korean DLBCL-NOS cohort differed notably, with MCD being significantly more prevalent. The MCD subtype tended to be associated with non–germinal center B-cell–like DLBCL and DLBCL with MYC/BCL2 double expression (DE). In R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone)-treated DLBCL-NOS, patients with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.
- 12 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 1929-1942
Open AccessDistribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel
Several molecular subclassifications of diffuse large B-cell lymphoma (DLBCL) with prognostic and therapeutic potential have been proposed; however, validation in diverse populations and real-world clinical settings remains limited. We investigated the genetic subtypes of Korean DLBCL using the LymphGen classifier and an institutionally developed 121-gene targeted next-generation sequencing (NGS) panel. We also assessed quality control metrics, copy number reliability, and benchmarking performance against an external reference data set (Memorial Sloan Kettering Cancer Center–Integrated Mutation Profiling Actionable Cancer Targets). LymphGen subtypes differed by entity. Patients with DLBCL, not otherwise specified (DLBCL-NOS; n = 123) were classified as MCD (25.2%), A53 (14.6%), ST2 (7.3%), BN2 (5.7%), EZB (3.3%), composite EZB/ST2 (1.6%), and unclassified (“other”; 42.3%). Patients with primary DLBCLs of the central nervous system (n = 77) were classified as MCD (70.1%), composite MCD/A53 (2.6%), A53 (3.9%), BN2 (2.6%), ST2 (1.3%), EZB (1.3%), and “other” (18.2%). Compared with Western cohorts, the LymphGen subtype distribution in our Korean DLBCL-NOS cohort differed notably, with MCD being significantly more prevalent. The MCD subtype tended to be associated with non–germinal center B-cell–like DLBCL and DLBCL with MYC/BCL2 double expression (DE). In R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone)-treated DLBCL-NOS, patients with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.
- Open Access
- 28 February 2025
- Published by The Korean Society for Legal Medicine in Korean Journal of Legal Medicine
- Vol. 49 (1) , 7-15
Fatal Non-thrombotic Pulmonary Embolism after Vaginal Filler Injection: A Report of Two Autopsy Cases and Literature Review
Non-thrombotic pulmonary embolism (NTPE) is a rare but potentially fatal complication of filler injections. It can result not only from direct intravascular injection but also from the migration of fillers into veins due to local pressure. Here, we report the autopsy findings of two deaths resulting from NTPE following vaginal filler injections. The first case involved a 38-year-old woman who lost consciousness 20-40 minutes after receiving an injection of 15 mL of hyaluronic acid (HA) filler. A large amount of filler was observed in the vagina with gross embolization of the paravaginal vessels. Microscopic examination revealed HA embolism in the lungs. Despite treatment, the patient died 10 days after the procedure. The second case involved a 35-year-old woman who experienced desaturation and cardiac arrest 4 minutes after receiving a collagen filler and a hybrid filler consisting of HA and polylactic acid. An autopsy revealed NTPE and systemic embolism of the collagen filler. She died 1 month after treatment in the intensive care unit. The vagina poses a significant risk for filler injections owing to its rich venous plexus. Doctors should be fully aware of this risk, and a complete autopsy should be performed in such cases.
- 28 February 2025
- Published by The Korean Society for Legal Medicine in Korean Journal of Legal Medicine
- Vol. 49 (1) , 7-15
Open AccessFatal Non-thrombotic Pulmonary Embolism after Vaginal Filler Injection: A Report of Two Autopsy Cases and Literature Review
Non-thrombotic pulmonary embolism (NTPE) is a rare but potentially fatal complication of filler injections. It can result not only from direct intravascular injection but also from the migration of fillers into veins due to local pressure. Here, we report the autopsy findings of two deaths resulting from NTPE following vaginal filler injections. The first case involved a 38-year-old woman who lost consciousness 20-40 minutes after receiving an injection of 15 mL of hyaluronic acid (HA) filler. A large amount of filler was observed in the vagina with gross embolization of the paravaginal vessels. Microscopic examination revealed HA embolism in the lungs. Despite treatment, the patient died 10 days after the procedure. The second case involved a 35-year-old woman who experienced desaturation and cardiac arrest 4 minutes after receiving a collagen filler and a hybrid filler consisting of HA and polylactic acid. An autopsy revealed NTPE and systemic embolism of the collagen filler. She died 1 month after treatment in the intensive care unit. The vagina poses a significant risk for filler injections owing to its rich venous plexus. Doctors should be fully aware of this risk, and a complete autopsy should be performed in such cases.
- Open Access
- 14 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5773-5788
Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL
The pathogenesis of myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) double-expressor diffuse large B-cell lymphoma (DE-DLBCL) remains unclear. To investigate how MYC and BCL2 contribute to tumor aggressiveness, we analyzed tumors from 14 patients each with DE-DLBCL and non–DE-DLBCL using whole transcriptome sequencing. Validation was performed using publicly available data sets, tumor tissues from 126 patients, DLBCL cell lines, and a syngeneic mouse lymphoma model. Our transcriptome analysis revealed significantly elevated messenger RNA levels of C-C motif chemokine ligand 2 (CCL2) and C-C chemokine receptor type 2 (CCR2) in DE-DLBCLs when compared with non–DE-DLBCLs (adjusted P value < .05). Transcriptomic analysis of public data sets and immunohistochemistry corroborated these findings, indicating increased levels of M2 macrophages but a reduction in T-cell infiltration in DE-DLBCLs when compared with non–DE-DLBCLs (all P < .05). CCR2 expression was observed mainly in tumor-infiltrating macrophages and not in DLBCL cells. Increased expression of CCL2 and CCR2 was significantly associated with a poor prognosis in patients with DLBCL. In the in vitro analyses, MYChigh/BCL2high DLBCL cells showed higher CCL2 expression and secretion than MYClow/BCL2low cells. MYC and BCL2 increased CCL2 expression and secretion by upregulation of nuclear factor κB p65 in DLBCL cells, and CCL2 promoted M2 polarization of macrophages. In a mouse lymphoma model, CCL2 contributed to the immunosuppressive microenvironment and tumor growth of MYChigh/BCL2high tumors. We demonstrated that the increased CCL2/CCR2 axis confers aggressiveness to DE-DLBCL by increasing M2 polarization and can be a potential therapeutic target.
- 14 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5773-5788
Open AccessIncreased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL
The pathogenesis of myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) double-expressor diffuse large B-cell lymphoma (DE-DLBCL) remains unclear. To investigate how MYC and BCL2 contribute to tumor aggressiveness, we analyzed tumors from 14 patients each with DE-DLBCL and non–DE-DLBCL using whole transcriptome sequencing. Validation was performed using publicly available data sets, tumor tissues from 126 patients, DLBCL cell lines, and a syngeneic mouse lymphoma model. Our transcriptome analysis revealed significantly elevated messenger RNA levels of C-C motif chemokine ligand 2 (CCL2) and C-C chemokine receptor type 2 (CCR2) in DE-DLBCLs when compared with non–DE-DLBCLs (adjusted P value < .05). Transcriptomic analysis of public data sets and immunohistochemistry corroborated these findings, indicating increased levels of M2 macrophages but a reduction in T-cell infiltration in DE-DLBCLs when compared with non–DE-DLBCLs (all P < .05). CCR2 expression was observed mainly in tumor-infiltrating macrophages and not in DLBCL cells. Increased expression of CCL2 and CCR2 was significantly associated with a poor prognosis in patients with DLBCL. In the in vitro analyses, MYChigh/BCL2high DLBCL cells showed higher CCL2 expression and secretion than MYClow/BCL2low cells. MYC and BCL2 increased CCL2 expression and secretion by upregulation of nuclear factor κB p65 in DLBCL cells, and CCL2 promoted M2 polarization of macrophages. In a mouse lymphoma model, CCL2 contributed to the immunosuppressive microenvironment and tumor growth of MYChigh/BCL2high tumors. We demonstrated that the increased CCL2/CCR2 axis confers aggressiveness to DE-DLBCL by increasing M2 polarization and can be a potential therapeutic target.
- Open Access
- 2 August 2024
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 32 (1) , 1-5
Isolated severe mitral stenosis as an uncommon manifestation of cardiac amyloidosis
- 2 August 2024
- Published by Springer Nature in Journal of Cardiovascular Imaging
- Vol. 32 (1) , 1-5
Open AccessIsolated severe mitral stenosis as an uncommon manifestation of cardiac amyloidosis
- 23 May 2024
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 24 (8) , 522
Liquid biopsies for Hodgkin lymphoma
- 23 May 2024
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 24 (8) , 522
Liquid biopsies for Hodgkin lymphoma
- Open Access
- 15 March 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (2) , 59-71
Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified
Background: The classification of nodal peripheral T-cell lymphoma (PTCL) has evolved according to histology, cell-of-origin, and genetic alterations. However, the comprehensive expression pattern of follicular helper T-cell (Tfh) markers, T-cell factor-1 (TCF1), and Th1- and Th2-like molecules in nodal PTCL is unclear.Methods: Eighty-two cases of nodal PTCL were classified into 53 angioimmunoblastic T-cell lymphomas (AITLs)/nodal T-follicular helper cell lymphoma (nTFHL)-AI, 18 PTCLs-Tfh/nTFHL–not otherwise specified (NOS), and 11 PTCLs-NOS according to the revised 4th/5th World Health Organization classifications. Immunohistochemistry for TCF1, TBX21, CXCR3, GATA3, and CCR4 was performed.Results: TCF1 was highly expressed in up to 68% of patients with nTFHL but also in 44% of patients with PTCL-NOS (p > .05). CXCR3 expression was higher in AITLs than in non-AITLs (p = .035), whereas GATA3 expression was higher in non-AITL than in AITL (p = .007) and in PTCL-Tfh compared to AITL (p = .010). Of the cases, 70% of AITL, 44% of PTCLTfh/ nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the TBX21 subtype; and 15% of AITL, 38% of PTCL-Tfh/nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the GATA3 subtype. The others were an unclassified subtype. CCR4 expression was associated with poor progression-free survival (PFS) in patients with PTCL-Tfh (p < .001) and nTFHL (p = .023). The GATA3 subtype showed poor overall survival in PTCL-NOS compared to TBX21 (p = .046) and tended to be associated with poor PFS in patients with non-AITL (p = .054).Conclusions: The TBX21 subtype was more prevalent than the GATA3 subtype in AITL. The GATA3 subtype was associated with poor prognosis in patients with non-AITL and PTCL-NOS.
- 15 March 2024
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 58 (2) , 59-71
Open AccessClinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified
Background: The classification of nodal peripheral T-cell lymphoma (PTCL) has evolved according to histology, cell-of-origin, and genetic alterations. However, the comprehensive expression pattern of follicular helper T-cell (Tfh) markers, T-cell factor-1 (TCF1), and Th1- and Th2-like molecules in nodal PTCL is unclear.Methods: Eighty-two cases of nodal PTCL were classified into 53 angioimmunoblastic T-cell lymphomas (AITLs)/nodal T-follicular helper cell lymphoma (nTFHL)-AI, 18 PTCLs-Tfh/nTFHL–not otherwise specified (NOS), and 11 PTCLs-NOS according to the revised 4th/5th World Health Organization classifications. Immunohistochemistry for TCF1, TBX21, CXCR3, GATA3, and CCR4 was performed.Results: TCF1 was highly expressed in up to 68% of patients with nTFHL but also in 44% of patients with PTCL-NOS (p > .05). CXCR3 expression was higher in AITLs than in non-AITLs (p = .035), whereas GATA3 expression was higher in non-AITL than in AITL (p = .007) and in PTCL-Tfh compared to AITL (p = .010). Of the cases, 70% of AITL, 44% of PTCLTfh/ nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the TBX21 subtype; and 15% of AITL, 38% of PTCL-Tfh/nTFHL-NOS, and 36% of PTCL-NOS were subclassified as the GATA3 subtype. The others were an unclassified subtype. CCR4 expression was associated with poor progression-free survival (PFS) in patients with PTCL-Tfh (p < .001) and nTFHL (p = .023). The GATA3 subtype showed poor overall survival in PTCL-NOS compared to TBX21 (p = .046) and tended to be associated with poor PFS in patients with non-AITL (p = .054).Conclusions: The TBX21 subtype was more prevalent than the GATA3 subtype in AITL. The GATA3 subtype was associated with poor prognosis in patients with non-AITL and PTCL-NOS.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (44) , e281
Diagnostic Value of Sternocleidomastoid Muscle Hemorrhage on Clavicular Periosteum in Hanging Deaths
Lim S, et al. J Korean Med Sci. 2024 Aug;39:e281. https://doi.org/10.3346/jkms.2024.39.e281
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (44) , e281
Open AccessDiagnostic Value of Sternocleidomastoid Muscle Hemorrhage on Clavicular Periosteum in Hanging Deaths
Lim S, et al. J Korean Med Sci. 2024 Aug;39:e281. https://doi.org/10.3346/jkms.2024.39.e281